Evome Medical Engages ICP Securities Inc. for Automated Market Making Services
Evome Medical Engages ICP Securities Inc. for Automated Market Making Services
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the " Company " or " Evome ") (TSXV: EVMT), is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprietary algorithm, ICP Premium, for its shares traded on the TSX Venture Exchange (the "TSXV"), in compliance with the policies of the TSXV and other applicable legislation. ICP will receive a fee of C$7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an initial term of four (4) months and shall be automatically renewed for subsequent one (1) month terms (each month called an "Additional Term") unless either party provides at least thirty (30) days written notice prior to the end of the initial term or an Additional Term, as applicable. There are no performance fees contained in the agreement and no stock options or other compensation are being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future.
紐約，2024年2月27日（GLOBE NEWSWIRE）——Evome Medical Technologies Inc.（“公司” 或 “Evome”）（多倫多證券交易所股票代碼：EVMT）欣然宣佈，它已聘請ICP Securities Inc.（“ICP”）提供自動化做市服務，包括使用其專有算法ICP Premium爲其在多倫多證券交易所風險交易所（“多倫多證券交易所”）交易的股票提供自動化做市服務，包括使用其專有算法ICP Premium”），符合多倫多證券交易所的政策和其他適用立法。ICP 每月將收取 7,500 加元的費用外加適用的稅費，按月提前支付。公司與ICP之間的協議初始期限爲四（4）個月，並應自動續訂隨後的一（1）個月期限（每個月稱爲 “附加期限”），除非任何一方在初始期限結束前至少三十（30）天書面通知或附加期限（如適用）。協議中不包含績效費，也沒有授予與聘用相關的股票期權或其他補償。ICP及其客戶將來可能會收購公司證券的權益。
ICP is an arm's length party to the Company, and, at the time of the agreement for ICP's services, to the knowledge of the Company, neither ICP nor its principals have an interest, directly or indirectly, in the securities of the Company. ICP's market making activity will be primarily to correct temporary imbalances in the supply and demand of the Company's shares. ICP will be responsible for the costs it incurs in buying and selling the Company's shares, and no third party will be providing funds or securities for the market making activities.
ICP是公司的正常交易方，據公司所知，在簽訂ICP服務協議時，ICP及其委託人均未直接或間接地在公司的證券中擁有權益。ICP的做市活動將主要是糾正公司股票供需的暫時失衡。ICP將承擔買入和賣出公司股票所產生的成本，任何第三方都不會爲做市活動提供資金或證券。
ICP Securities Inc.
ICP 證券公司
ICP Securities Inc. (ICP) is a Toronto based CIRO dealer-member that specializes in automated market making and liquidity provision, as well as having a proprietary market making algorithm, ICP Premium, that enhances liquidity and quote health. Established in 2023, with a focus on market structure, execution, and trading, ICP has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors.
ICP Securities Inc.（ICP）是一家總部位於多倫多的CIRO交易商成員，專門從事自動化做市和流動性供應，並擁有專有的做市算法ICP Premium，可增強流動性和報價健康狀況。ICP成立於2023年，專注於市場結構、執行和交易，利用自己的專有技術爲衆多公開發行人和機構投資者提供高質量的流動性提供和執行服務。
For more information please contact:
欲了解更多信息，請聯繫：
Mike Seckler
Chief Executive Officer
Evome Medical Technologies Inc.
Tel: 1 (800) 760-6826
Email: info@evomemedical.com
邁克·塞克勒
首席執行官
Evome 醫療技術公司
電話：1 (800) 760-6826
電子郵件：info@evomemedical.com
Additional Information
附加信息
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在the 多倫多證券交易所風險投資交易所的policies 中定義）均不對本release 的充分性或準確性承擔責任。
譯文內容由第三人軟體翻譯。